# YiPSCELL

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/yipscell

- Industry: Pharmaceuticals
- Headquarters: Seoul, South Korea
- Website: www.yipscell.com
- Total disclosed funding: $11M
- Latest round: Series A (Jun 7, 2021)
- Investors on record: 4

## About

Established in 2017 and based in Seoul, South Korea, YiPSCELL Co., Ltd. is a company based on induced multifunctional stem cell technology that provides disease modeling services. In March 2010, the company established the CiSTEM Research Laboratory. In June 2021, the company raised KRW 12 billion in series A funding led by new investor InterVest, with participation from other new investors AJU IB Investment, HB Investment, and Premier Partners. The company has obtained more than five patents.

The company uses induced multifunctional stem cell technology to develop therapeutic agents that are effective for patients and to provide researchers with a research platform. The company also develops stem cell-based therapeutic agents. The research of the company include MIUChon™, MIUKin™, MIURon™, MIUHeart™, MIUBon™, and Exosome™. The company also provides cell line service and analysis service.

## Funding rounds

- Series A, Jun 7, 2021, $11M — AJU IB Investment, InterVest, HB Investment, Premier Partners

## Investors

- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Series A
- InterVest (https://capitalatlas.ai/funds/intervest) — Series A
- HB Investment (https://capitalatlas.ai/funds/hb-investment) — Series A
- Premier Partners (https://capitalatlas.ai/funds/premier-partners) — Series A